These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 18972868)

  • 1. [Therapeutic approaches for treatment of Creutzfeldt-Jakob disease].
    Heinemann U; Weiss S; Zerr I
    Med Monatsschr Pharm; 2008 Oct; 31(10):378-84. PubMed ID: 18972868
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Prospects of the therapeutic approaches to Creutzfeldt-Jakob disease: a clinical trial of antimalarial, quinacrine].
    Furukawa H; Takahashi M; Nakajima M; Yamada T
    Nihon Rinsho; 2002 Aug; 60(8):1649-57. PubMed ID: 12187766
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Therapeutic prospects for subacute transmissible spongiform encephalopathies].
    Seman M; Adjou KT
    Rev Prat; 1999 May; 49(9):971-5. PubMed ID: 11865463
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [But there was something ...?].
    Oberpichler-Schwenk H
    Med Monatsschr Pharm; 2008 Oct; 31(10):371. PubMed ID: 18972866
    [No Abstract]   [Full Text] [Related]  

  • 5. Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects.
    Benito-León J
    Neurology; 2005 May; 64(10):1824; author reply 1824. PubMed ID: 15911834
    [No Abstract]   [Full Text] [Related]  

  • 6. Different prion conformers target the olfactory pathway in sporadic Creutzfeldt-Jakob disease.
    Zanusso G; Ferrari S; Benedetti D; Sbriccoli M; Rizzuto N; Monaco S
    Ann N Y Acad Sci; 2009 Jul; 1170():637-43. PubMed ID: 19686205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Amantadine in the treatment of Creutzfeldt-Jakob disease.
    Braham J
    Arch Neurol; 1984 Jun; 41(6):585-6. PubMed ID: 6372758
    [No Abstract]   [Full Text] [Related]  

  • 8. Bilateral vestibular failure as an early sign in Creutzfeldt-Jakob disease.
    Jahn K; Arbusow V; Zingler VC; Strupp M; Kretzschmar HA; Brandt T
    Ann N Y Acad Sci; 2009 May; 1164():390-3. PubMed ID: 19645934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Risk factors for sporadic Creutzfeldt-Jakob disease].
    Kittner C; Heinemann U; Zerr I
    Dtsch Med Wochenschr; 2009 Jul; 134(27):1429-35. PubMed ID: 19551608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Eleven years of autopsy on account of Creutzfeldt-Jakob disease in the Netherlands].
    Jansen C; Schuur M; Spliet WG; van Gool WA; van Duijn CM; Rozemuller AJ
    Ned Tijdschr Geneeskd; 2009; 153():A172. PubMed ID: 19785859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prion safety of transfusion plasma and plasma-derivatives typically used for prophylactic treatment.
    Svae TE; Neisser-Svae A; Bailey A; Reichl H; Biesert L; Schmidt T; Heger A; Römisch J
    Transfus Apher Sci; 2008 Aug; 39(1):59-67. PubMed ID: 18619902
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Creutzfeldt-Jakob disease: a disease overview.
    Cyngiser TA
    Am J Electroneurodiagnostic Technol; 2008 Sep; 48(3):199-208. PubMed ID: 18998478
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pathologic correlates of diffusion MRI changes in Creutzfeldt-Jakob disease.
    Manners DN; Parchi P; Tonon C; Capellari S; Strammiello R; Testa C; Tani G; Malucelli E; Spagnolo C; Cortelli P; Montagna P; Lodi R; Barbiroli B
    Neurology; 2009 Apr; 72(16):1425-31. PubMed ID: 19380702
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Old drugs to treat new variant Creutzfeldt-Jakob disease.
    Love R
    Lancet; 2001 Aug; 358(9281):563. PubMed ID: 11520533
    [No Abstract]   [Full Text] [Related]  

  • 15. [Creutzfeldt-Jakob disease and its therapeutic approaches].
    Sakasegawa Y; Doh-Ura K
    Nihon Rinsho; 2011 Dec; 69 Suppl 10 Pt 2():411-4. PubMed ID: 22755224
    [No Abstract]   [Full Text] [Related]  

  • 16. Loss of cerebellar granule neurons is associated with punctate but not with large focal deposits of prion protein in Creutzfeldt-Jakob disease.
    Faucheux BA; Privat N; Brandel JP; Sazdovitch V; Laplanche JL; Maurage CA; Hauw JJ; Haïk S
    J Neuropathol Exp Neurol; 2009 Aug; 68(8):892-901. PubMed ID: 19606064
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quinacrine in possible or probable CJD: it is blinded investigators, not patients, who must be in equipoise over treatment.
    Cooper E
    BMJ; 2002 Jan; 324(7331):239. PubMed ID: 11831208
    [No Abstract]   [Full Text] [Related]  

  • 18. Bone marrow stroma cells are susceptible to prion infection.
    Takakura Y; Yamaguchi N; Nakagaki T; Satoh K; Kira J; Nishida N
    Biochem Biophys Res Commun; 2008 Dec; 377(3):957-61. PubMed ID: 18976632
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An update on the assessment and management of the risk of transmission of variant Creutzfeldt-Jakob disease by blood and plasma products.
    Turner ML; Ludlam CA
    Br J Haematol; 2009 Jan; 144(1):14-23. PubMed ID: 18950452
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI lesion profiles in sporadic Creutzfeldt-Jakob disease.
    Meissner B; Kallenberg K; Sanchez-Juan P; Collie D; Summers DM; Almonti S; Collins SJ; Smith P; Cras P; Jansen GH; Brandel JP; Coulthart MB; Roberts H; Van Everbroeck B; Galanaud D; Mellina V; Will RG; Zerr I
    Neurology; 2009 Jun; 72(23):1994-2001. PubMed ID: 19506221
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.